BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsConference / presentation

PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026

Related news

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

CRNXCrinetics Pharmaceuticals2026-05-22 20:05 EST

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

PTCTPTC Therapeutics, Inc.2026-05-04 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

RAREUltragenyx Pharmaceutical2026-06-03 20:30 EST

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

RAREUltragenyx Pharmaceutical2026-05-06 20:30 EST

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

BCRXBioCryst Pharmaceuticals2026-04-28 11:00 EST

BioCryst to Present at Upcoming Investor Conferences

EDITEditas Medicine2026-05-28 20:01 EST

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

BCRXBioCryst Pharmaceuticals2026-05-13 11:00 EST

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

KRYSKrystal Biotech2026-05-07 12:00 EST

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

ARWRArrowhead Pharmaceuticals2026-08-03 20:30 EST

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWRArrowhead Pharmaceuticals2026-07-27 11:30 EST

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Stock data

Close
85.83 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States